could only be administered via central line so not suitable for solid tumours, which severally limited commercial opportunities since the 80’s till now.
RC220 tox studies wrap up in the next few weeks into straight into trials. Timing is good for newbies as they don’t have missed out on the 3-year wait reformulating RC220.
could only be administered via central line so not suitable for...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.045(3.14%) |
Mkt cap ! $248.8M | |||
| Open | High | Low | Value | Volume |
| $1.42 | $1.48 | $1.41 | $74.60K | 51.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6944 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 3096 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.47 |
Change
0.045 ( 1.69 %) |
||||
| Open | High | Low | Volume | ||
| $1.41 | $1.48 | $1.41 | 21844 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| RAC (ASX) Chart |